• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Lineage Cell Therapeutics, Inc.

    3/16/21 5:04:53 PM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $LCTX alert in real time by email
    SC 13D/A 1 d8824804_13d-a.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

    SCHEDULE 13D

    THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 24)

     

     

    Lineage Cell Therapeutics, Inc.
    (Name of Issuer)

     

     

    Common Shares, no par value
    (Title of Class of Securities)

     

     

    53566P109
    (CUSIP Number)

     

     

    Neal C. Bradsher

    c/o Broadwood Capital, Inc.

    142 West 57th Street, 11th Floor

    New York, New York 10019

    (212) 508-5735

    (Name, Address and Telephone Number of Person Authorized to Receive

    Notices and Communications)

     

     

    March 11, 2021
    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [_].
     
     
     
    CUSIP No. 53566P109    
         

     

    1. NAME OF REPORTING PERSONS  
         
      Broadwood Partners, L.P.  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
        (a)   [_]
        (b)   [X]
         
    3. SEC USE ONLY  
         
         
         
    4. SOURCE OF FUNDS  
         
      WC  
         
    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)   [_]
         
         
         
    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
         
    7. SOLE VOTING POWER  
         
      0  
         
    8. SHARED VOTING POWER  
         
      34,005,379  
         
    9. SOLE DISPOSITIVE POWER
         
      0  
         
    10. SHARED DISPOSITIVE POWER    
         
      34,005,379  
     

     

     
    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING  
      PERSON  
         
      34,005,379  
         
    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES  
      CERTAIN SHARES [_]
         
         
    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      21.0%  
         
    14. TYPE OF REPORTING PERSON  
         
      PN  
         
         
         

     

     
     

     

    CUSIP No. 53566P109    
         

     

    1. NAME OF REPORTING PERSONS  
         
      Broadwood Capital, Inc.  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
        (a)   [_]
        (b)   [X]
         
    3. SEC USE ONLY  
         
         
         
    4. SOURCE OF FUNDS  
         
      AF  
         
    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)   [_]
         
         
         
    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      New York  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
         
    7. SOLE VOTING POWER  
         
      0  
         
    8. SHARED VOTING POWER  
         
      34,005,379  
         
    9. SOLE DISPOSITIVE POWER
         
      0  
         
    10. SHARED DISPOSITIVE POWER    
         
      34,005,379  

     

       
    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING  
      PERSON  
         
      34,005,379  
         
    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES  
      CERTAIN SHARES [_]
         
         
    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      21.0%  
         
    14. TYPE OF REPORTING PERSON  
         
      CO, IA  
         
         
         

     

     
     

     

    CUSIP No. 53566P109    
         

     

    1. NAME OF REPORTING PERSONS  
         
      Neal C. Bradsher  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
        (a)   [_]
        (b)   [X]
         
    3. SEC USE ONLY  
         
         
         
    4. SOURCE OF FUNDS  
         
      PF, AF, OO  
         
    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)   [_]
         
         
         
    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
         
    7. SOLE VOTING POWER  
         
      241,788  
         
    8. SHARED VOTING POWER  
         
      34,005,379  
         
    9. SOLE DISPOSITIVE POWER
         
      241,788  
         
    10. SHARED DISPOSITIVE POWER    
         
      34,005,379  

     

       
    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING  
      PERSON  
         
      34,247,167  
         
    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES  
      CERTAIN SHARES [_]
         
         
    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      21.2%  
         
    14. TYPE OF REPORTING PERSON  
         
      IN, HC  
         
         
         

     

     
     

     

    CUSIP No. 53566P109    
         
    Item 1. Security and Issuer.  
         
     

    The name of the issuer is Lineage Cell Therapeutics, Inc., a California corporation (the “Issuer”). The address of the Issuer’s principal executive office is 2173 Salk Avenue, Suite 200, Carlsbad, California 92008. This Amendment No. 24 to Schedule 13D relates to the Issuer’s Common Shares, no par value (the “Shares”).

     

     
         

     

    Item 2. Identity and Background.  
         
      (a), (f) The persons filing this statement are: (i) Broadwood Partners, L.P., a Delaware limited partnership ("Broadwood Partners"); (ii) Broadwood Capital, Inc., a New York corporation ("Broadwood Capital"); and (iii) Neal C. Bradsher, a United States citizen (“Mr. Bradsher”, and collectively with Broadwood Partners and Broadwood Capital, the "Reporting Persons").  
           
      (b), (c) Broadwood Capital is an investment adviser registered with the Securities and Exchange Commission that is principally engaged in the business of providing investment advisory services.  Broadwood Partners is a pooled investment vehicle that is principally engaged in the business of investing its assets in securities.  Broadwood Capital serves as the general partner of Broadwood Partners.  Neal Bradsher is the President of Broadwood Capital.  The principal business address of the Reporting Persons is: c/o Broadwood Capital, Inc., 142 West 57th Street, 11th Floor, New York, New York 10019.    
           
      (d) None of the Reporting Persons have, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).  
           
      (e)

    None of the Reporting Persons have, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

     
           
    Item 3. Source and Amount of Funds or Other Consideration.  
           
     

    The funds for the purchase of the 34,005,379 Shares beneficially owned by Broadwood Partners came from its working capital. No borrowed funds were used to purchase the Shares, other than any borrowed funds used for working capital purposes in the ordinary course of business.

     

    The funds for the purchase of the 34,005,379 Shares beneficially owned by Broadwood Capital came from the working capital of Broadwood Partners, which is the direct owner of the Shares. No borrowed funds were used to purchase the Shares, other than any borrowed funds used for working capital purposes in the ordinary course of business.

     

    The funds for the purchase of the 34,247,167 Shares beneficially owned by Mr. Bradsher came from his personal funds and the working capital of Broadwood Partners. Certain of the Shares beneficially owned by Mr. Brasher were granted to him by the Issuer as compensation for his service as a member of the Issuer’s board of directors (the “Board of Directors”). No borrowed funds were used to purchase the Shares, other than any borrowed funds used for working capital purposes in the ordinary course of business.

     

     
           

     

     
     

     

     

    Item 4. Purpose of Transaction.  
         
     

    The Reporting Persons acquired their Shares for investment purposes and are filing this Schedule 13D/A to report a change in their respective beneficial ownership percentages of the Shares resulting from an increase in the Issuer’s outstanding Shares.

     

    Mr. Bradsher serves on the Board of Directors.

     

    Except as otherwise set forth below, the Reporting Persons do not have any present plans or proposals which would relate to, or result in, the matters set forth in subparagraphs (a) – (j) of Item 4 of Schedule 13D. However, subject to market conditions and in compliance with applicable securities laws, the Reporting Persons reserve the right, at a later date, to effect one or more of such changes or transactions in the number of Shares they may be deemed to beneficially own in open-market or privately negotiated transactions, on such terms and at such times as the Reporting Persons may deem advisable.

     

     
      The Reporting Persons have been and may continue to be in contact with members of the Board of Directors, other significant shareholders and others regarding alternatives and strategies that the Issuer could employ to significantly increase shareholder value over time.  Among these alternatives are additional improvements to the Board of Directors and management, as well as refinements to the Issuer's strategy that may improve its business, accelerate its progress with respect to its major growth opportunities, and realize the value of its non-strategic assets.  The Reporting Persons further reserve the right to act in concert with any other shareholders of the Issuer, or other persons, for a common purpose should they determine to do so, and/or to recommend courses of action to shareholders, the Board of Directors and/or the management of the Issuer.  
           
           

     

    Item 5. Interest in Securities of the Issuer.  
         
      (a) – (d) As of the date hereof, Broadwood Partners may be deemed to be the beneficial owner of 34,005,379 Shares, constituting 21.0% of the Shares, based upon 161,637,890 Shares outstanding as of the date hereof.  Broadwood Partners has the sole power to vote or direct the vote of 0 Shares and the shared power to vote or direct the vote of 34,005,379 Shares.  Broadwood Partners has sole power to dispose or direct the disposition of 0 Shares and the shared power to dispose or direct the disposition 34,005,379 Shares.  
           
        As of the date hereof, Broadwood Capital may be deemed to be the beneficial owner of 34,005,379 Shares, constituting 21.0% of the Shares, based upon 161,637,890 Shares outstanding as of the date hereof.  Broadwood Capital has the sole power to vote or direct the vote of 0 Shares and the shared power to vote or direct the vote of 34,005,379 Shares.  Broadwood Capital has sole power to dispose or direct the disposition of 0 Shares and the shared power to dispose or direct the disposition 34,005,379 Shares.  
           
       

    As of the date hereof, Mr. Bradsher may be deemed to be the beneficial owner of 34,247,167 Shares, constituting 21.2% of the Shares, based upon 161,816,770 Shares outstanding as of the date hereof, as adjusted to include stock options of the Issuer beneficially owned by Mr. Bradsher. Mr. Bradsher has the sole power to vote or direct the vote of 241,788 Shares and the shared power to vote or direct the vote of 34,005,379 Shares. Mr. Bradsher has sole power to dispose or direct the disposition of 241,788 Shares and the shared power to dispose or direct the disposition 34,005,379 Shares.

     

    There have been no transactions in the Shares by the Reporting Persons during the past sixty days.

     

     
      (e) N/A  
           

     

     
     

     

     

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect  
      to Securities of the Issuer.  
     

     

    The information set forth in Item 4 above is incorporated by reference in its entirety in this Item 6. The Reporting Persons do not have any contract, arrangement, understanding or relationship with any person with respect to securities of the Issuer that is not described herein and/or in a previous Schedule 13D filed by the Reporting Persons in respect of the Issuer.

     

     
         

     

    Item 7. Material to be Filed as Exhibits.  
         
     

    Exhibit A: Joint Filing Agreement.

     

     
         

     

     
     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Dated:  March 16, 2021

    Broadwood Partners, L.P.*

     

      By: Broadwood Capital, Inc.
       
      By: /s/ Neal C. Bradsher
      Name: Neal C. Bradsher
      Title: President
         
     

     

     

     
      Broadwood Capital, Inc.*
       
      By: /s/ Neal C. Bradsher
      Name: Neal C. Bradsher
      Title: President
     

     

     

     
       
      /s/ Neal C. Bradsher
      Neal C. Bradsher*
       

     

     

    * This Reporting Person disclaims beneficial ownership over the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     
     

    Exhibit A

    JOINT FILING AGREEMENT

    The undersigned agree that this Amendment No. 24 to Schedule 13D, dated March 16, 2021, relating to the Common Shares, no par value, of Lineage Cell Therapeutics, Inc. shall be filed on behalf of the undersigned.

     

    Dated:  March 16, 2021

    Broadwood Partners, L.P.

     

      By: Broadwood Capital, Inc.
       
      By: /s/ Neal C. Bradsher
      Name: Neal C. Bradsher
      Title: President
         
       

     

     

      Broadwood Capital, Inc.
       
      By: /s/ Neal C. Bradsher
      Name: Neal C. Bradsher
      Title: President
       

     

     

         
      /s/ Neal C. Bradsher
      Neal C. Bradsher

     

     

     

     

     

     

     

     

    Get the next $LCTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LCTX

    DatePrice TargetRatingAnalyst
    8/20/2024$4.00Buy
    Craig Hallum
    11/2/2022$5.00Outperform
    Robert W. Baird
    6/14/2022$4.00Buy
    B. Riley Securities
    8/19/2021$8.00Outperform
    Noble Capital Markets
    More analyst ratings

    $LCTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Lineage Cell Therapeutics with a new price target

      Craig Hallum initiated coverage of Lineage Cell Therapeutics with a rating of Buy and set a new price target of $4.00

      8/20/24 8:32:59 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Robert W. Baird initiated coverage on Lineage Cell Therapeutics with a new price target

      Robert W. Baird initiated coverage of Lineage Cell Therapeutics with a rating of Outperform and set a new price target of $5.00

      11/2/22 6:28:33 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • B. Riley Securities initiated coverage on Lineage Cell Therapeutics with a new price target

      B. Riley Securities initiated coverage of Lineage Cell Therapeutics with a rating of Buy and set a new price target of $4.00

      6/14/22 7:59:45 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LCTX
    SEC Filings

    See more
    • Lineage Cell Therapeutics Inc. filed SEC Form 8-K: Other Events

      8-K - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)

      5/1/25 9:09:09 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Lineage Cell Therapeutics Inc.

      DEFA14A - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)

      4/29/25 4:10:04 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Lineage Cell Therapeutics Inc.

      DEF 14A - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)

      4/29/25 4:05:15 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LCTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its first quarter 2025 financial and operating results on Tuesday, May 13, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Tuesday, May 13, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2025 financial and operating results and to provide a business update. Conference Call and Webcast Interested parties may access the conference call on May 13, 2025, by dialing (800) 7

      5/1/25 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium

      Fully Virtual Event Scheduled for June 27, 2025 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, and the Christopher & Dana Reeve Foundation, a non-profit organization dedicated to advancing innovative research and improving quality of life for individuals impacted by paralysis, are proud to collaborate and present the 3rd Annual Spinal Cord Injury Investor Symposium ("3rd SCIIS"). This year's event aims to bring together companies working in the development of treatments for SCI, with regulators, key opinion leaders, persons with lived experience, patient and community advoc

      4/22/25 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)

      Lineage Participating in Panel Discussion of Novel Retina Drug Delivery Approaches at Eyecelerator@ Park City 2025 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage's Chief Executive Officer, has been invited to join presenters from REGENXBIO Inc., Regenerative Patch Technologies, LLC, Neurotech Pharmaceuticals, Inc., and others, as part of the "I Shall Be Released: Novel Drug Delivery Approaches for Glaucoma and Retina" panel at Eyecelerator@ Park City 2025. The panel will take place on Friday, May 2, 2025 from 12:30pm to 1:30pm M

      4/21/25 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LCTX
    Financials

    Live finance-specific insights

    See more
    • Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its first quarter 2025 financial and operating results on Tuesday, May 13, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Tuesday, May 13, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2025 financial and operating results and to provide a business update. Conference Call and Webcast Interested parties may access the conference call on May 13, 2025, by dialing (800) 7

      5/1/25 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its fourth quarter and full year 2024 financial and operating results on Monday, March 10, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Monday, March 10, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2024 financial and operating results and to provide a business update. Interested parties may access the conference call on Monday, March 10, 2025, by di

      3/5/25 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

      OpRegen® Granted Regenerative Medicine Advanced Therapy (RMAT) Designation From FDA ReSonance™ (ANP1) Preclinical Results Presented at 59th Annual Inner Ear Biology Workshop Added to 2024 Russell 3000® Index Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its third quarter 2024 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a business update. "We were delighted to see our partners' continued commitment to the OpRegen program, in this instance by seeking

      11/14/24 4:01:00 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LCTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

      Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins Clinical Session Expanded to Include Neuralink Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical   Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced updates to its 2nd Annual Spinal Cord Injury Investor Symposium ("2nd SCIIS"). The 2nd SCIIS aims to accelerate development in SCI research and treatments by bringing together companies working in the development of treatments for SCI, with regulators, key opinion leaders, persons with lived exp

      5/21/24 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture investment across a broad range of therapeutic modalities and development stages, and has a proven ability to combine deep scientific expertise and business development acumen to identify innovative opportunities to drive both returns and impact. Dr. Hubbert previously served as Partner and Head of Gates Foundation Venture

      4/1/24 8:00:00 AM ET
      $LCTX
      $SYBX
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Lineage Announces Appointment of General Counsel

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it has appointed George A. Samuel III as Lineage's General Counsel and Corporate Secretary. Mr. Samuel will lead the Company's legal operations, bringing extensive corporate, transactional, intellectual property and commercial expertise which spans nearly 15 years across the life sciences and technology sectors as well as in private practice. "We are pleased to welcome George to our leadership team and look forward to his contributions as we build Lineage into a leading cell therapy and cell transplant comp

      9/1/21 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LCTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by President and CEO Culley Brian M

      4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

      3/12/25 5:30:54 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Howe Jill Ann

      4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

      3/12/25 5:30:36 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by General Counsel and Secretary Samuel George A. Iii

      4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

      3/12/25 5:30:11 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LCTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Broadwood Partners, L.P. bought $6,000,000 worth of shares (7,894,737 units at $0.76) (SEC Form 4)

      4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

      1/28/25 7:49:41 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Howe Jill Ann bought $8,850 worth of shares (15,000 units at $0.59), increasing direct ownership by 143% to 25,500 units (SEC Form 4)

      4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

      11/26/24 4:58:31 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • General Counsel Samuel George A. Iii bought $9,000 worth of shares (15,000 units at $0.60), increasing direct ownership by 209% to 22,184 units (SEC Form 4)

      4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

      11/26/24 4:55:46 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LCTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Lineage Cell Therapeutics Inc.

      SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)

      11/21/24 8:05:56 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Lineage Cell Therapeutics Inc. (Amendment)

      SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)

      2/8/24 6:57:07 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Lineage Cell Therapeutics Inc. (Amendment)

      SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)

      3/25/22 5:23:02 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care